Pfizer

This study tests a new pneumococcal vaccine (PG4) in healthy children aged 15 months to 18 years. About 1,200 participants will receive either the new vaccine or the current Prevnar 20. Researchers will compare safety and immune response over 6 months. The goal is to see if the n…

This study tests a vaccine given to pregnant women to see if it can protect their babies from group B streptococcus (GBS) infection, a serious illness in newborns. Healthy pregnant women aged 49 or younger, between 24 and 36 weeks of pregnancy, can join. Participants receive one …

This study tests a new pneumococcal vaccine in healthy infants to see if it is safe and works better than the current vaccine. About 3,230 babies will receive either the new vaccine or the existing one at routine checkups. Researchers will compare side effects and immune response…

This study tests an RSV vaccine in adults aged 18-59 who have health conditions like chronic lung, heart, or kidney disease that put them at higher risk for severe RSV. The goal is to see if the vaccine triggers a strong immune response and is safe. Participants receive one shot …

This study tests a new pneumococcal vaccine in about 2400 healthy infants starting at 2 months old. The goal is to see if the new vaccine is as safe as the current vaccine, Prevnar 20, and if it can protect against more types of bacteria that cause pneumonia, meningitis, and ear …

This study tests whether a vaccine can prevent C. difficile infection in adults 65 and older. About 32,000 participants will receive either the vaccine or a placebo shot. The study will track infections and side effects over up to three and a half years.

This study is testing how well a 20-valent pneumococcal vaccine works against pneumonia in adults aged 65 and older. Researchers will compare vaccinated and unvaccinated hospitalized patients with pneumonia to see if the vaccine reduces infections from seven specific bacterial st…

This study tests whether a fifth dose of Pfizer's Lyme disease vaccine (VLA15) is safe and boosts immunity in people who already received four doses. About 1,700 healthy volunteers aged 7 and older will get either the vaccine or a saltwater shot. Researchers will compare side eff…

This Pfizer study tests several experimental mRNA-based flu vaccines in 770 healthy adults aged 18 and older. Participants receive one dose and are monitored for about 6 months for safety and immune response. The goal is to see if these new vaccines are safe and trigger a strong …

Pfizer is testing several experimental vaccines designed to protect against E. coli bacteria. This early-stage study involves 310 healthy adults aged 18 to 64. The main goal is to check if the vaccines are safe and tolerable, not yet whether they work. Participants will receive t…

This study is checking how safe the Prevenar 20 vaccine is once it's used in Korea. About 660 people aged 6 weeks and older who are prescribed the vaccine will get one dose. Researchers will track any side effects for 28 days after vaccination.

This early-stage trial is testing a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors that have a specific BRAF gene change. The drug is given alone or combined with other medicines like binimetinib or cetuximab. The study aims to find safe doses …

This study looks at the long-term safety and effectiveness of a medicine called marstacimab for people with severe hemophilia A or B. Participants receive regular injections to help prevent bleeding episodes. The goal is to see if this treatment is safe and reduces bleeds over ti…

This phase 3 trial tests a new antiviral pill, ibuzatrelvir, alone or with an IV drug (remdesivir) in 300 adults with weak immune systems who have mild-to-moderate COVID-19. The goal is to see if the combination prevents hospitalizations or worsening symptoms better than remdesiv…

This study tests an oral medication called ibuzatrelvir in adults and teens with COVID-19 who are not hospitalized but have a high risk of becoming severely ill. Participants will receive either the drug or a placebo for 5 days, and researchers will track whether it reduces emerg…

This study offers ongoing access to the drug elranatamab for people with multiple myeloma who were already benefiting from it in earlier Pfizer studies. The goal is to keep providing the treatment while monitoring for any side effects. About 80 participants will take part, and th…

This Phase 3 trial tests whether adding the experimental drug mevrometostat to the standard drug enzalutamide can slow cancer growth better than enzalutamide alone. It involves 900 men with metastatic castration-resistant prostate cancer who have not yet tried certain hormone the…

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This study tests a new IV antibiotic (aztreonam-avibactam) in hospitalized children aged 9 months to 18 years with serious gram-negative bacterial infections. About 48 participants will receive either the new drug or the best available standard treatment. The goal is to see how t…

This study tests whether rimegepant, a dissolving tablet, can prevent migraines in children and adolescents ages 6 to under 18. About 640 participants will receive either the drug or a placebo for 12 weeks. The main goal is to see if the drug reduces the number of migraine days p…

This early-phase study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…

This study tests a new drug called elranatamab for people with multiple myeloma that has returned or stopped responding to treatment. Half of the 492 participants will get elranatamab as a weekly shot; the other half will get one of several standard drug combinations. The goal is…

This study tests whether adding the experimental drug mevrometostat to the standard treatment enzalutamide can slow down cancer growth better than enzalutamide alone. It involves 1000 men with metastatic prostate cancer that still responds to hormone therapy. Participants will be…

This study tests whether giving a second dose of an RSV vaccine to pregnant women who already received it in a prior pregnancy is safe and boosts immunity. About 550 women aged 18-49, between 24-36 weeks pregnant, will receive either the vaccine or a placebo. Researchers will tra…

This early-stage study tests a new experimental drug, PF-08103402, for the first time in people. It includes healthy adults and adults with mild-to-moderate asthma to check safety, how the drug moves through the body, and whether food affects its absorption. Participants take the…

This study tests a daily pill called etrasimod in 24 children aged 2 to 12 with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. The goal is to see if the drug can safely help children reach remission (few or no symptoms) over 52 weeks. Participants wh…

This study tests whether a new drug combination (elranatamab, daratumumab, and lenalidomide) works better than a standard combination for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The trial involves about 1,116 participants and …

This study tests a once-monthly injection called berobenatide to help adults with overweight or obesity lose weight. About 954 participants will receive either the drug or a placebo for 20 months. The goal is to see if the drug is safe and effective for weight loss, including in …

This study looks at how well etrasimod works for people with moderate to severe ulcerative colitis when used in normal doctor visits. About 360 adults aged 18 to 65 will take etrasimod as prescribed by their doctor and fill out health questionnaires online. Researchers will track…

This study tests an experimental drug called PF-07275315 in adults with moderate-to-severe COPD who have had at least two flare-ups in the past year. Participants receive either the drug or a placebo as injections over several months. The goal is to see if the drug improves lung …

This study tests a combination of two antibiotics, aztreonam and avibactam, in newborns and infants up to 9 months old who have serious infections caused by gram-negative bacteria. The trial has two parts: one to see how a single dose moves through the body, and another to test m…

This Phase 3 study tests whether taking rimegepant (a dissolving tablet) for 7 days around each period can prevent menstrual migraines in women aged 18-45. About 723 women with regular cycles and a history of menstrual migraines will receive either rimegepant or a placebo. The go…

This early-stage study is testing whether a combination of two drugs—elranatamab (given as a shot) and iberdomide (taken as a pill)—is safe and tolerable for people with multiple myeloma that has returned or stopped responding to prior treatments. The trial will enroll about 87 p…

This study tests a drug called inotuzumab ozogamicin (Besponsa) against standard chemotherapy for children aged 1 to 17 with high-risk B-cell acute lymphoblastic leukemia that has returned after initial treatment. The goal is to see if the targeted drug can clear more cancer cell…

This large phase 3 trial is testing a new once-weekly injection called MET097 for weight loss in 3501 adults with obesity or overweight (but without diabetes). Participants will receive either the drug or a placebo for up to 84 weeks. The main goal is to see how much weight peopl…

This study tests two experimental drugs, PF-08653945 and PF-08653944, given alone or together, for weight loss in adults with overweight or obesity. About 872 participants will receive either the drugs or a placebo injection. The main goal is to see how much weight they lose over…

This study tests a new experimental drug, PF-08634404, combined with chemotherapy in people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new…

This study tests a daily medication called etrasimod in 36 adolescents aged 12 to 17 with moderate-to-severe ulcerative colitis. The goal is to see if the drug can safely help control the disease and reduce inflammation over a year, with an option to continue treatment for up to …

This study tests a new medicine called PF-08634404, given alone or with chemotherapy, for adults with early or locally advanced non-small cell lung cancer. The trial has three parts: before surgery, after surgery if cancer remains, or after chemoradiation. Researchers will check …

This study tests whether a new experimental drug called PF-08634404, given with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to rec…

This study tests a new medicine called PF-08634404 given with chemotherapy for adults with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. The trial has two parts: first checking safety, then comparing the new combo to an approved treatment (atezoli…

This study tests a new drug called PF-08634404, given alone or with another drug (ipilimumab), in adults with advanced liver cancer that cannot be surgically removed. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 138 participants will recei…

This study tests a new medicine, PF-08634404, in adults with advanced bladder cancer that has spread. Some participants receive the drug alone, while others get it combined with another cancer drug. The goal is to check safety, how well it works, and how it affects the body. Abou…

This study tests a new medicine called PF-08634404 given with chemotherapy for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer that develops from another lung cancer type. About 40 participants will receive the drug combo through IV infusions…

This study tests a new medicine, PF-08634404, in adults with advanced kidney cancer that has spread. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer drugs. About 224 participants who have not had prior treatment for their advanced…

This study tests a new experimental drug called PF-08634404 combined with other cancer medicines in people with advanced non-small cell lung cancer that has spread and can't be surgically removed. The trial has two parts: one combining PF-08634404 with sigvotatug vedotin, and ano…

This Phase 3 trial is testing whether a new medicine called PF-08634404, combined with standard chemotherapy, works better than the current treatment Avastin plus chemo for people whose colorectal cancer has spread. About 800 participants who have not had prior treatment for meta…

This study tests whether combining two experimental drugs, MET233 and MET097, can help adults with obesity or overweight lose weight, including those with type 2 diabetes. About 381 participants will receive either the drug combination or a placebo to check safety and how well th…

This Phase 3 trial tests a drug called dazukibart in people with active dermatomyositis or polymyositis, rare diseases that cause muscle weakness and inflammation. About 318 adults will receive either the drug or a placebo by IV every 4 weeks for 48 weeks. The study aims to see i…

This study follows 850 people with alopecia areata who are taking the approved drug ritlecitinib in real-world clinics. Researchers will measure hair regrowth using the SALT score over 24 weeks. The goal is to see how well the drug works outside of controlled trials, in everyday …

This early-stage study tests a new drug, PF-07994525, in about 120 adults with advanced multiple myeloma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. The study has two parts:…

This early-stage study tests a new medicine called marstacimab in people with severe hemophilia A who want to switch from their current preventive treatment, emicizumab. The study includes 15 adolescents and adults who will receive weekly injections of marstacimab for 4 months. R…

This study tests an experimental pill (PF-07328948) for adults with heart failure. About 620 participants will receive either the drug or a placebo to see if it improves walking distance and heart-related symptoms over 36 weeks. The goal is to manage the condition and reduce the …

This study is testing a new medicine called PF-07868489 for people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lung arteries makes the heart work harder. The study is open-label, meaning everyone knows they are getting the drug, and it…

This study is monitoring the safety and effectiveness of Litfulo (Ritlecitinib) in 3,000 people with severe alopecia areata, a condition causing patchy hair loss. Participants take the drug as prescribed in real-world clinics across Korea. Researchers will track side effects and …

This study looks at the safety and effectiveness of Velsipity tablets taken daily for up to 52 weeks by people with moderate to severe ulcerative colitis. About 553 participants will be followed in real-world medical settings. The goal is to see if the drug can help control sympt…

This Phase 3 trial tests a new medicine called MET097, given as a weekly injection, to help adults with overweight or obesity and type 2 diabetes lose weight. About 999 people will take part, with two-thirds getting the real drug and one-third getting a placebo. The study lasts a…

This study tests the long-term safety and effectiveness of dazukibart in people with dermatomyositis or polymyositis, rare diseases that cause muscle weakness and rashes. Participants who completed a previous study can join. Some will receive the drug via IV every 4 weeks for abo…

This study tests an experimental drug called PF-06835375 in adults with moderate to severe primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The goal is to see if the drug can safely increase platelet counts. Abo…

This study tests a new medicine called marstacimab in children aged 1 to 17 with severe hemophilia A or B. The medicine is given as a weekly shot under the skin to prevent bleeding episodes. Researchers will compare how well it works to the children's own past year of standard tr…

This early-stage study is testing a new oral drug, PF-08032562, in people with advanced breast or colorectal cancer that has spread. The drug is given alone or with other cancer treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. Abo…

This study tests whether abrocitinib, a liquid medicine, can improve moderate-to-severe eczema in children aged 6 to 12. About 150 kids will be randomly assigned to receive either the drug or a placebo for 16 weeks. The goal is to see if the medicine clears the skin and reduces i…

This study tests a new drug called elranatamab, alone or with another drug (daratumumab), against a standard three-drug combo for people with multiple myeloma that came back or didn't respond after at least one prior treatment. About 944 participants will be randomly assigned to …

This Phase 3 trial is testing whether a new drug called PF-07248144, taken with fulvestrant, can help people with a common type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatment. About 400 participants will either receive the new co…

This study looks at how effective and safe the drug lorlatinib is for people with a specific type of lung cancer (ALK-positive non-small cell lung cancer) who have not had treatment before. Researchers will follow 90 patients in French clinics to see how long they live without th…

This study tests a new medicine called PF-07275315 for adults with moderate-to-severe asthma that is not well controlled. Participants will receive either the drug or a placebo as injections over 12 weeks. The goal is to see if the drug improves lung function and is safe. About 2…

This study looks at the long-term safety and effects of the drug ritlecitinib for severe alopecia areata, a condition causing significant hair loss. It involves 140 teens who previously completed Pfizer studies on this drug. Participants take a daily capsule for up to 3 years, wi…

This study watches 300 adults with moderate to severe ulcerative colitis who are prescribed etrasimod by their doctor. Researchers track symptoms like stool frequency and rectal bleeding over 52 weeks using health questionnaires. The goal is to see how well the drug works outside…

This study tests a daily pill called ritlecitinib for adults with moderate to severe hidradenitis suppurativa (HS), a condition causing painful red skin lumps. About 240 participants who haven't been helped by antibiotics will be randomly assigned to get the drug or a placebo for…

This study is tracking 150 adults and teens with moderate-to-severe eczema who have already tried up to two biologic drugs without success. Researchers want to see how well the oral medication abrocitinib (Cibinqo) works in real-world settings. The main goals are to measure impro…

This early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…

This study tests a drug called disitamab vedotin in 100 adults with advanced breast cancer that has spread and is hard to treat. Participants must have tumors with HER2 protein and have had prior treatment. They receive the drug into a vein every two weeks. Researchers will check…

This study tests a new drug called PF-08052667 for adults with a type of bladder cancer that hasn't spread into the muscle layer but is likely to return. The drug is given directly into the bladder, sometimes with other medicines like BCG or sasanlimab. The trial has three parts …

This study compares an experimental drug (PF-08046054) to standard chemotherapy (docetaxel) in about 680 adults with advanced PD-L1 positive non-small cell lung cancer that has worsened after prior treatments. Participants are randomly assigned to receive one of the two drugs by …

This Phase 3 trial tests whether adding Sigvotatug Vedotin to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has high levels of PD-L1. About 714 participants will receive either the combinati…

This early-stage study tests a new experimental drug called PF-07934040, taken as a pill, for people with advanced solid tumors that have a KRAS gene mutation. The trial includes patients with non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Researchers will …

This study tests a new drug called PF-07248144, alone or combined with other cancer treatments, in people with advanced breast, prostate, or lung cancers that have not responded to standard therapy. The trial aims to find safe doses and check for early signs of tumor shrinkage. A…

This study is observing 600 people with chronic myeloid leukemia (CML) who are taking BOSULIF as part of their normal treatment in Korea. Researchers will track side effects and how well the drug controls the disease over time. The goal is to see if BOSULIF works safely in everyd…

This 24-month study tests the long-term safety and effectiveness of abrocitinib, a liquid oral medication, in children aged 2 and older with moderate-to-severe atopic dermatitis (eczema). About 500 participants will receive the drug, with or without topical creams. The goal is to…

This early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…

This study gives people who are already benefiting from the cancer drugs encorafenib and/or binimetinib in earlier trials continued access to these medicines for up to 5 years. It includes safety monitoring and is open to about 46 participants whose doctors confirm they are still…

This study tracks the safety and effectiveness of the arthritis drug Xeljanz XR in about 200 adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Participants take the drug as prescribed by their doctor, and researchers record any s…

This study tracks 600 Korean patients with ALK-positive metastatic lung cancer who are taking Lorviqua as part of their normal care. Researchers will monitor side effects and how well the drug controls the cancer in everyday practice. The goal is to confirm the drug's safety and …

This study tests an oral drug called osivelotor in about 389 adults and adolescents with sickle cell disease. The goal is to see if it can raise hemoglobin levels and reduce the number of painful vaso-occlusive crises. Participants will take the pill daily, and researchers will m…

This study is monitoring the safety and effects of Mylotarg in 165 adults in Korea who are newly diagnosed with acute myeloid leukemia (AML). Participants will receive Mylotarg as part of their routine care, and researchers will track any side effects and how the disease responds…

This study looks at the safety and effectiveness of the drug Xeljanz in children aged 2 to 17 with active juvenile idiopathic arthritis or juvenile psoriatic arthritis. It is an observational study in Korean clinics, meaning doctors prescribe the drug as usual and researchers mon…

This study is monitoring the safety and effectiveness of the prescription drug Cibinqo (abrocitinib) in people with moderate to severe atopic dermatitis (a type of eczema). About 1,100 participants in Korea will take the tablet as prescribed by their doctor and be observed for on…

This study is tracking 183 adults with moderate-to-severe atopic dermatitis (eczema) who are taking abrocitinib, a daily tablet. Researchers want to see how well the drug works in real-life settings, not just in controlled clinical trials. Participants will be followed for 24 mon…

This program provides early access to ritlecitinib for people with severe alopecia areata who have lost at least half of their scalp hair and have not responded to or cannot tolerate standard treatments. The goal is to offer a potential treatment option before the drug is fully a…

This program provides early access to the drug etrasimod for people with ulcerative colitis who have tried at least three other treatments without success or cannot use them. The goal is to offer a potential treatment option when no standard therapies are left. Patients must meet…

This study follows 200 people aged 12 and older with moderate-to-severe eczema who are starting a new prescription of abrocitinib. Researchers will track how much their skin improves over 12 months using standard eczema severity scores. The goal is to see how well the drug works …

This study tests whether the medicine rimegepant can prevent migraines in teenagers aged 12 to 17 who have frequent, long-lasting headaches. About 200 teens will take either rimegepant or a placebo every other day for 3 months, then all will receive rimegepant for a year. The goa…

This study tests a drug called ponsegromab combined with standard chemotherapy to see if it helps adults with advanced pancreatic cancer who are losing weight and appetite (cachexia). About 982 participants will receive either ponsegromab or a placebo alongside their first chemot…

This study looks at whether taking a second dose of the migraine medication rimegepant is safe and helpful for adults whose migraine pain isn't fully relieved by the first dose. About 400 people aged 18 and older with a history of migraines will take part. Researchers will track …

This study tests whether rimegepant, a fast-dissolving tablet, can safely relieve migraine pain in children and adolescents aged 6 to 18. About 2,100 participants will receive either the drug or a placebo during a migraine attack. The main goal is to see if more kids become pain-…

This study tests the long-term safety of rimegepant, a migraine medication taken as a dissolving tablet, in children and adolescents aged 6 to 18. About 600 participants with a history of migraine will take the drug as needed for up to one year. The main goal is to check for side…

This study tests an experimental daily pill, ritlecitinib, for adults with chronic spontaneous urticaria (long-term itchy hives and swelling) that antihistamines don't fully control. About 200 participants will receive either 50 mg, 100 mg, or a placebo for 12 weeks, then all wil…

This study tests an experimental daily tablet (PF-08049820) for adults with moderate to severe eczema (atopic dermatitis). About 165 participants will take either the study drug or a placebo for 12 weeks. Researchers will check skin improvement, itching, and safety through clinic…

This study tests two experimental injectable drugs (PF-07275315 and PF-07264660) for adults with moderate to severe atopic dermatitis (eczema) that hasn't improved with skin creams. About 340 participants will receive the drugs or a placebo over up to 13 months to see if the medi…

This study looks at possible eye-related side effects in people with cervical cancer that has returned or spread, who are being treated with the drug TIVDAK. About 100 participants will receive TIVDAK every 3 weeks and undergo regular eye exams before, during, and after treatment…

This early-stage study tests an experimental drug called PF-07832837 in healthy adults and people with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. Researchers will also look for early signs that the drug…

This early-stage study is testing a nasal spray called zavegepant in 16 children aged 6 to 12 who have had migraines for at least 6 months. The main goal is to see if the drug is safe and how the body handles it. Each child gets a single dose based on their weight, and the study …

This Pfizer study in 9 healthy men uses a tiny amount of radioactive carbon to track how the experimental drug PF-07799544 is absorbed, distributed, and eliminated from the body. Participants receive the drug by mouth and by IV, and samples of blood, urine, and stool are collecte…

This study looks at how the experimental drug PF-08049820 is absorbed in healthy adults. It tests three different forms of the drug, taken with or without food, and also with another drug that reduces stomach acid. The goal is to understand the best way to give the drug in future…

This study checks if a new melt-in-the-mouth version of a migraine drug works the same as the approved tablet. It involves 36 healthy adults who will take both forms at different times. The goal is to see if the body absorbs the drug similarly, not to treat migraines.

This study is watching for side effects in 50 children in India who are prescribed somatrogon, a long-acting growth hormone injection for growth hormone deficiency. The goal is to see how safe the drug is during routine care over 3 years. Participants do not have to visit the cli…

This early-stage study tests a new medicine, PF-08057418, in healthy adults to see if it is safe and how the body processes it. Eight participants will receive single doses (as a solution or tablet) once a week for 5 weeks. The study is not intended to treat any disease, but to g…

This early-stage study by Pfizer looks at how different levels of liver function affect the processing of a new drug called PF-07328948. About 26 adults with and without liver impairment will take a single tablet and stay at the clinic for 6 days for monitoring and blood tests. T…

This study follows 173 people with hemophilia A or B who previously received a single-dose gene therapy in a Pfizer trial. Researchers will track bleeding episodes, clotting factor levels, and any long-term side effects like blood clots or liver issues. The goal is to understand …

This study tests whether two different injector pens deliver the same amount of Genotropin (a growth hormone) into the blood. About 26 healthy adults aged 18 to 60 will receive a single shot with each pen and have blood samples taken. The goal is to see if the pens work equally w…

This study looks at how the medicine PF-07328948 moves through the body in adults with different levels of kidney function. About 28 people aged 18 to 80, with either normal kidneys or moderate-to-severe kidney problems, will take a single tablet. Researchers will check safety an…

This study follows pregnant women with migraine who took rimegepant (Nurtec) and those who did not, to compare rates of birth defects and other pregnancy complications. About 780 participants will be tracked through 12 months after birth. The goal is to gather safety data, not to…

This study is for healthy men aged 18-64 to see how the experimental drug PF-07328948 is absorbed and removed from the body. Participants will take the drug by mouth and by injection, and provide blood, urine, and stool samples. The study does not aim to treat any disease, just t…

This early-stage study is testing an investigational drug called PF-08653944 in 26 adults, some with healthy livers and others with mild to severe liver impairment. Researchers want to see how liver function affects the way the body processes the drug and whether it is safe. Part…

This early-stage study tests an experimental drug called PF-08653944 in 20 overweight or obese adults. Researchers want to see how it affects the speed at which the stomach empties food, using a common painkiller as a marker. The main goals are to understand the drug's effects an…

This study is testing how much of the drug etrasimod ends up in breast milk. Eight healthy breastfeeding women will take a 2 mg pill daily for a week while staying at a clinic. They will not breastfeed their babies during the study to keep them safe. Researchers will measure drug…

This study looks at how the body handles a single dose of the drug vepdegestrant in people with moderate to severe liver problems compared to healthy people. About 24 adults (ages 18-70) will take one pill and stay at the clinic for 11 days. The goal is to see if liver function a…

This study is tracking 1,500 Swedish patients with metastatic breast cancer who are taking palbociclib as part of their treatment. Researchers want to see how long patients stay on the drug, what their characteristics are, and how they fare over time. It's an observational study,…

This early-stage study tests a new medicine called PF-07985631, which may one day treat a kidney disease called IgA nephropathy. About 92 healthy adults will receive either the study drug or a placebo as an injection or IV. The main goal is to check safety and how the body proces…

This early-stage study tests a new medicine, PF-07985631, in healthy adults to check its safety and how the body processes it. The medicine is being developed for a kidney disease called IgA nephropathy. Participants receive either the drug or a placebo as a single injection and …

This study follows 400 pregnant women with eczema to see if the drug abrocitinib (CIBINQO) is safe during pregnancy. Half the women take the drug, the other half do not. Researchers track birth defects and infant health up to 12 months after birth. No extra doctor visits are need…

This early-stage study by Pfizer will give atirmociclib to 72 healthy adults to see how the drug moves through the body at different doses after a meal. Participants will receive four single doses in a random order, with blood samples taken to measure drug levels. The goal is to …

This study observes 600 patients in Korea who receive Zavicefta for complicated abdominal or urinary tract infections or hospital-acquired pneumonia. Researchers track side effects and how well the drug works. It is required by Korean regulators to ensure the drug's safety after …